CL2013000736A1 - Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos. - Google Patents

Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.

Info

Publication number
CL2013000736A1
CL2013000736A1 CL2013000736A CL2013000736A CL2013000736A1 CL 2013000736 A1 CL2013000736 A1 CL 2013000736A1 CL 2013000736 A CL2013000736 A CL 2013000736A CL 2013000736 A CL2013000736 A CL 2013000736A CL 2013000736 A1 CL2013000736 A1 CL 2013000736A1
Authority
CL
Chile
Prior art keywords
imidazol
phenyl
wet
ethyl
prepare
Prior art date
Application number
CL2013000736A
Other languages
English (en)
Inventor
Mohammed I Dibas
Daniel W Gil
Ken Chow
Liming Wang
Michael E Garst
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000736(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2013000736A1 publication Critical patent/CL2013000736A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de prodrogas éster de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento útil en el tratamiento de enfermedades de la retina tales como degeneración macular húmeda y seca, y retinopatía diabética; y uso de la composición que comprende a dichos compuestos.
CL2013000736A 2010-09-16 2013-03-18 Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos. CL2013000736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16

Publications (1)

Publication Number Publication Date
CL2013000736A1 true CL2013000736A1 (es) 2013-07-12

Family

ID=44675870

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2013000735A CL2013000735A1 (es) 2010-09-16 2013-03-18 Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CL2013000734A CL2013000734A1 (es) 2010-09-16 2013-03-18 Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.
CL2013000736A CL2013000736A1 (es) 2010-09-16 2013-03-18 Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.
CL2013000733A CL2013000733A1 (es) 2010-09-16 2013-03-18 Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2013000735A CL2013000735A1 (es) 2010-09-16 2013-03-18 Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CL2013000734A CL2013000734A1 (es) 2010-09-16 2013-03-18 Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2013000733A CL2013000733A1 (es) 2010-09-16 2013-03-18 Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.

Country Status (28)

Country Link
US (9) US8501796B2 (es)
EP (13) EP3053576B1 (es)
JP (4) JP6073229B2 (es)
KR (7) KR20140005154A (es)
CN (5) CN105412092B (es)
AR (4) AR083020A1 (es)
AU (4) AU2011301856C1 (es)
BR (4) BR112013006355A2 (es)
CA (8) CA3116249A1 (es)
CL (4) CL2013000735A1 (es)
CY (3) CY1121024T1 (es)
DK (9) DK3636263T3 (es)
ES (10) ES2607084T3 (es)
HU (5) HUE049573T2 (es)
IL (4) IL225282A0 (es)
MX (4) MX2013003009A (es)
MY (4) MY161607A (es)
NZ (1) NZ608751A (es)
PL (7) PL3050563T3 (es)
PT (7) PT3338777T (es)
RU (4) RU2013116405A (es)
SG (4) SG188572A1 (es)
SI (5) SI3050563T1 (es)
TR (1) TR201909249T4 (es)
TW (4) TW201305116A (es)
UA (1) UA112973C2 (es)
WO (4) WO2012037484A1 (es)
ZA (4) ZA201302194B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2395999B1 (en) * 2009-02-13 2017-09-13 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
MX2014000871A (es) * 2011-07-22 2014-06-23 Allergan Inc Moduladores adrenergicos alfa-2 para el tratamiento de trastornos visuales mediados por proyecciones visuales centrales desde el ojo.
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN112552314B (zh) * 2018-08-24 2022-03-04 杭州阿诺生物医药科技有限公司 Sting激动剂小分子抗肿瘤化合物及其应用
BR112023021140A2 (pt) * 2021-04-16 2023-12-12 Ads Therapeutics Llc Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica
KR20250141793A (ko) * 2023-02-08 2025-09-29 보슈 롬 아일랜드 리미티드 시력을 개선시키기 위한 알파-2-아드레날린성 효능제
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2004106307A2 (fr) * 2003-05-27 2004-12-09 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
EP1658717A1 (en) * 2003-07-14 2006-05-24 Koninklijke Philips Electronics N.V. Projection device
MXPA06002716A (es) 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
CN101426502A (zh) 2004-05-25 2009-05-06 桑斯罗萨医药发展公司 治疗或预防炎症性皮肤疾病的化合物、制剂及方法
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
WO2006036480A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
CA2751651A1 (en) 2009-02-06 2010-08-12 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
EP2395999B1 (en) * 2009-02-13 2017-09-13 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure

Also Published As

Publication number Publication date
TW201240662A (en) 2012-10-16
CA2812195A1 (en) 2012-03-22
PT2616068T (pt) 2016-09-13
AR083018A1 (es) 2013-01-23
JP2013540749A (ja) 2013-11-07
RU2013116403A (ru) 2014-10-27
AU2011301901B2 (en) 2016-02-11
US20120142746A1 (en) 2012-06-07
ES2904479T3 (es) 2022-04-05
EP3050563B1 (en) 2018-05-09
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
KR101840501B1 (ko) 2018-05-04
HUE038698T2 (hu) 2018-11-28
CL2013000733A1 (es) 2013-08-23
EP2616067A1 (en) 2013-07-24
AU2011301847A1 (en) 2013-05-02
AU2011301932B2 (en) 2016-02-25
IL225278A0 (en) 2013-06-27
US8501796B2 (en) 2013-08-06
EP3348264A1 (en) 2018-07-18
PL3050564T3 (pl) 2020-06-01
BR112013006355A2 (pt) 2016-06-28
ES2607084T3 (es) 2017-03-29
CA2812191A1 (en) 2012-03-22
PL3050563T3 (pl) 2018-12-31
CN103221045A (zh) 2013-07-24
EP2616069B1 (en) 2016-11-16
WO2012037499A1 (en) 2012-03-22
CA3079450A1 (en) 2012-03-22
WO2012037484A1 (en) 2012-03-22
SI3348264T1 (sl) 2020-07-31
PL2616068T3 (pl) 2016-11-30
PT3050564T (pt) 2019-12-11
WO2012037490A1 (en) 2012-03-22
EP3053576A1 (en) 2016-08-10
CA2812191C (en) 2021-04-13
EP3659600A1 (en) 2020-06-03
DK3078376T3 (da) 2019-06-24
HUE039090T2 (hu) 2018-12-28
ES2788051T3 (es) 2020-10-20
CN105412092B (zh) 2020-11-17
ES2760920T3 (es) 2020-05-18
TW201240661A (en) 2012-10-16
MX2013003004A (es) 2013-06-28
PL3338777T3 (pl) 2020-07-13
HK1185539A1 (zh) 2014-02-21
ES2593612T3 (es) 2016-12-12
CN103209694A (zh) 2013-07-17
US20160354346A1 (en) 2016-12-08
DK2616069T3 (en) 2016-12-19
ES2684055T3 (es) 2018-10-01
CA2812197A1 (en) 2012-03-22
PT3053576T (pt) 2018-10-08
SI3050564T1 (sl) 2020-02-28
CN103200941B (zh) 2015-12-16
IL225280A0 (en) 2013-06-27
WO2012037453A1 (en) 2012-03-22
ZA201302193B (en) 2013-11-27
US20130296394A1 (en) 2013-11-07
AR083019A1 (es) 2013-01-23
DK3053576T3 (en) 2018-08-20
EP2616068B1 (en) 2016-07-13
HK1185540A1 (en) 2014-02-21
KR102139905B1 (ko) 2020-07-31
DK3636263T3 (da) 2022-01-10
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
HK1257416A1 (en) 2019-10-18
PL2616069T3 (pl) 2017-04-28
EP3050563A1 (en) 2016-08-03
US20150148394A1 (en) 2015-05-28
IL225278A (en) 2015-11-30
MY191369A (en) 2022-06-20
EP3050564B1 (en) 2019-09-04
TW201305117A (zh) 2013-02-01
CN103200941A (zh) 2013-07-10
DK3050564T3 (da) 2019-11-25
CA2811559A1 (en) 2012-03-22
AU2011301932C1 (en) 2016-09-01
KR102104760B1 (ko) 2020-04-27
CL2013000735A1 (es) 2013-11-29
US8492422B2 (en) 2013-07-23
PL3348264T3 (pl) 2020-08-24
ZA201302288B (en) 2013-11-27
US8653123B2 (en) 2014-02-18
EP3050564A1 (en) 2016-08-03
MX2013003009A (es) 2013-06-28
EP3636263A1 (en) 2020-04-15
US20120122945A1 (en) 2012-05-17
AR083020A1 (es) 2013-01-23
TWI591058B (zh) 2017-07-11
DK3338777T3 (da) 2020-04-20
SG188571A1 (en) 2013-04-30
UA112973C2 (uk) 2016-11-25
BR112013006320B1 (pt) 2022-08-30
EP3053576B1 (en) 2018-05-16
JP6073229B2 (ja) 2017-02-01
EP2616069A1 (en) 2013-07-24
AU2011301847B2 (en) 2016-02-11
EP2616068A1 (en) 2013-07-24
TW201305116A (zh) 2013-02-01
ES2781681T3 (es) 2020-09-04
SI3053576T1 (sl) 2018-11-30
KR20190022895A (ko) 2019-03-06
HUE048725T2 (hu) 2020-09-28
DK2616068T3 (en) 2016-08-29
KR102354097B1 (ko) 2022-01-20
RU2612351C2 (ru) 2017-03-07
CA3116249A1 (en) 2012-03-22
CA2812197C (en) 2024-01-02
ES2613509T3 (es) 2017-05-24
EP3338777A1 (en) 2018-06-27
AU2011301932A1 (en) 2013-05-02
EP3338777B1 (en) 2020-02-05
IL225282A0 (en) 2013-06-27
SG188573A1 (en) 2013-04-30
EP3078376A1 (en) 2016-10-12
HUE047476T2 (hu) 2020-04-28
JP2013537236A (ja) 2013-09-30
ES2737230T3 (es) 2020-01-10
US8853251B2 (en) 2014-10-07
RU2013116405A (ru) 2014-10-27
MX2013003002A (es) 2013-06-28
DK3050563T3 (en) 2018-08-13
KR20200044147A (ko) 2020-04-28
PT3348264T (pt) 2020-04-02
CA3077732A1 (en) 2012-03-22
RU2013116541A (ru) 2014-10-27
CY1122809T1 (el) 2021-05-05
MY161607A (en) 2017-04-28
ZA201302194B (en) 2013-11-27
KR101952457B1 (ko) 2019-02-26
EP3348264B1 (en) 2020-01-01
EP2616066A1 (en) 2013-07-24
PL3053576T3 (pl) 2018-11-30
KR101840500B1 (ko) 2018-03-20
BR112013006320A2 (pt) 2016-06-21
EP2616066B1 (en) 2016-07-13
JP2013537237A (ja) 2013-09-30
AU2011301856A1 (en) 2013-05-02
BR112013006352A2 (pt) 2016-06-28
CY1122958T1 (el) 2021-10-29
HK1185541A1 (zh) 2014-02-21
MY168763A (en) 2018-12-04
SI3050563T1 (sl) 2018-10-30
PT2616069T (pt) 2016-12-06
AU2011301901A1 (en) 2013-05-02
EP2616067B1 (en) 2016-05-18
CL2013000734A1 (es) 2013-11-08
MY173846A (en) 2020-02-24
KR20140003407A (ko) 2014-01-09
EP3698789A1 (en) 2020-08-26
KR20130114140A (ko) 2013-10-16
CN105412092A (zh) 2016-03-23
DK3348264T3 (da) 2020-03-23
EP3078376B1 (en) 2019-03-27
CN103200942A (zh) 2013-07-10
TR201909249T4 (tr) 2019-07-22
US8492557B2 (en) 2013-07-23
US20130289088A1 (en) 2013-10-31
JP2013541527A (ja) 2013-11-14
CY1121024T1 (el) 2019-12-11
ES2687420T3 (es) 2018-10-25
SG188572A1 (en) 2013-04-30
SG188570A1 (en) 2013-04-30
CA3122745A1 (en) 2012-03-22
US20120149746A1 (en) 2012-06-14
HUE049573T2 (hu) 2020-10-28
US20140057958A1 (en) 2014-02-27
JP6045495B2 (ja) 2016-12-14
US20120136036A1 (en) 2012-05-31
HK1185538A1 (zh) 2014-02-21
IL225281A0 (en) 2013-06-27
PT3338777T (pt) 2020-05-06
NZ608751A (en) 2015-04-24
EP3636263B1 (en) 2021-11-03
PT3050563T (pt) 2018-10-01
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
KR20200091507A (ko) 2020-07-30
AU2011301856C1 (en) 2016-09-08
MX2013003008A (es) 2013-06-28
SI3338777T1 (sl) 2020-08-31

Similar Documents

Publication Publication Date Title
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
UY31079A1 (es) Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitógenos
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
UY31228A1 (es) Ariloxazoles sustituidos y su uso
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
CL2009000048A1 (es) Uso de compuestos derivados de triterpenoides en el tratamiento de insuficiencia renal, y enfermedades asociadas tales como: nefropatías, resistencia a la insulina, diabetes, patologías vasculares, entre otras.
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
UY33598A (es) Imidazopiridazinas sustituidas
CU20090148A7 (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
NI201400070A (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido.
HK1205461A1 (zh) 用於眼部传输治疗剂的组合物和方法
ECSP088989A (es) (aza)ciclohexanos carboxilados nuevos como ligandos de receptores de dopamina d3
BRPI0910368B8 (pt) uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores
GT201400043A (es) Imidazopiridazinas sustituidas con amino
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
BR112013006320A2 (pt) pró-fármacos de ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol
SV2011003871A (es) Tratamiento sistemico de parasitos hematofagos y consumidores de sangre por administracion oral de un agente antiparasitario
MX2016001006A (es) Policonjugados para suministro de desencadenantes de acido ribonucleico de interferencia (arni) en celulas tumorales en vivo.
BR112015001697A2 (pt) formulações de clomazona
CL2014001244A1 (es) Uso de una composicion farmaceutica que comprende un derivado de 4-pregenen-11beta-17-21-triol-3,20-diona para tratar una condicion ocular tal como presion intraocular elevada, glaucoma, uveitis, degeneracion macular, retinopatia diabetica, rosacea ocular, desprendimiento de retina, entre otras.
CL2010001459A1 (es) Compuesto derivados de benzoxazinona; compuesto intermediarios; composicion y combinacion farmaceutica; y uso para el trratamiento de enfermedades tales como insuficiencia respiratoria en el adulto, enfisema pulmonar, bronquitis, epoc, entre otras.
CL2015001318A1 (es) Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras.
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BR112012023747A2 (pt) compostos de adenosina e seu uso